Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Natera, Inc. - Common Stock (NQ: NTRA )

144.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
How Do Investors Really Feel About Natera?
Via Benzinga
Why Is Natera (NTRA) Stock Soaring Today
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 5.2% in the afternoon session after stocks rebounded, following a broad-based sell-off the previous day. The Nasdaq was down 4%, while the... 
Via StockStory
Topics Stocks World Trade
Exposures Tariff US Equities
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
From Natera, Inc.
Via Business Wire
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
From Natera, Inc.
Via Business Wire
Deep Dive Into Natera Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Natera (NASDAQ:NTRA) Reports Bullish Q4, Guides for Strong Full-Year Sales
Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 53% year on year to $476.1 million. The company’s full-year revenue... 
Via StockStory
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
From Natera, Inc.
Via Business Wire
Natera (NTRA) Q4 Earnings: What To Expect
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
From Natera, Inc.
Via Business Wire
Why NATERA INC (NASDAQ:NTRA) qualifies as a high growth stock.
Should you consider NATERA INC (NASDAQ:NTRA) for high growth investing? A fundamental and technical analysis of (NASDAQ:NTRA). 
Via Chartmill
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA).
Exploring high growth characteristics of NATERA INC (NASDAQ:NTRA). A fundamental and technical analysis of (NASDAQ:NTRA). 
Via Chartmill
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
From Natera, Inc.
Via Business Wire
Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4
Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent... 
Via Benzinga
NATERA INC is setting up nicely for a breakout.
Exploring NATERA INC's Technical Signals and Breakout Potential: A technical analysis of NATERA INC (NASDAQ:NTRA) shows it may be setting up for a breakout. 
Via Chartmill
The S&P 500 Fights Through Challenging Headlines To Close At New Weekly All-Time Highs
In this video lesson, I review the resilient overall market, stocks on my radar for the short and long-term portfolio, and a new EOD swing trade, for Tuesday's session. Happy trading. Aloha. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Looking Into Natera's Recent Short Interest
Via Benzinga
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
From Natera, Inc.
Via Business Wire
Small- To Mid-Cap Biotech Trades Poised For Gains
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these... 
Via Talk Markets
Topics ETFs Stocks / Equities
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Natera to Present New Data at the 2025 ASCO GI Symposium
From Natera, Inc.
Via Business Wire
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
The company is working to expand the uses and reimbursement for its blood-based tests for cancer. 
Via Investor's Business Daily
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,... 
Via Benzinga
The End Of The 60/40 Portfolio
Since bonds don't protect against stock declines, it's time for a different approach. 
Via Benzinga
Topics Bonds
Exposures Debt Markets
Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
From Natera, Inc.
Via Business Wire
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.